Date: 06 Aug 2012
The lifetime cost of hepatocellular carcinoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hepatocellular carcinoma (HCC) is the second most common cancer in Taiwan. For males in Taiwan, it is the most dangerous cancer, with both the highest incidence and mortality rate.
To determine cancer-related medical care costs for long-term survivors of HCC.
The estimation of the lifetime cost was based on the insurer perspective and adopted an incidence-based approach. Data was sourced from the 1999–2002 cancer registry statistics of patients with HCC and the claims data of Taipei Veterans General Hospital (TVGH). In total there were 2873 HCC patients at TVGH. In addition to this data, the research used population National Health Insurance claims data from the National Health Research Institutes (1996–2002) as the comparison group. The probabilities of survival, dying of cancer or dying of other causes were estimated using cancer registry statistics. To estimate lifetime (10-year) cost, we divided the disease process into three phases: initial, continuing and terminal. The cost of HCC was calculated as the sum of the average cost of each phase. The expected lifetime cost for treatment of an HCC patient was estimated by incorporating the phase-specific costs with the survival and mortality rates.
The results showed that 895 patients survived <1 year, and treatment for each of these patients cost on average New Taiwan dollars ($NT) 206 573 ($US1 = $NT33, year 2002 value) over this period. For those who survived ≥1 year, the terminal phase of treatment resulted in the highest costs, $NT237 032. On average, for each patient, the initial phase cost was $NT140 403 and the monthly cost for the continuing phase was $NT8687. For the average HCC patient, the 10-year lifetime cost was $NT418 554 (in nominal $NT).
Our study showed that the terminal phase cost the most out of the three treatment phases. The aggregate lifetime cost of HCC is useful for health policy making and clinical decision making.
Wang CP. The relationship between cancer incidence and cancer mortality in Taiwan [thesis]. Taichung: China Medical University, 2003
Department of Health, the Executive Yuan. Cancer registry annual report in Taiwan Area, 2001. Taipei: Department of Health, the Executive Yuan, 2004
Lee CL, Ko YC, Choong CS. Survival rate for liver cancer in Taiwan. Zhonghua Yi Xue Za Zhi 2000 Jan; 63(1): 16–20PubMed
Chen CJ, You SL, Lin LH, et al. Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 2002 Mar; 32 Suppl.: S66–81
Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796–800PubMed
Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications, 1997
Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002 Aug; 40(8 Suppl.): 104–17
- The lifetime cost of hepatocellular carcinoma
Applied Health Economics and Health Policy
Volume 6, Issue 1 , pp 55-65
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Institute of Hospital and Health Care Administration, National Yang-Ming University, Taiwan, No. 155 Li-Nong Street, Taipei, 112, Taiwan
- 2. School of Medicine, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
- 3. Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan
- 4. Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan
- 5. School of Medicine, Institute of Health and Welfare Policy, National Yang-Ming University, Taipei, Taiwan
- 6. Population and Health Research Center, Bureau of Health Promotion, Department of Health, Taichung, Taiwan